Company ProfilePremium

Nyxoah S.A.

Company Profile Analysis

Ticker: NYXH.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Nyxoah S.A. - Company showcase

Year Founded & Workforce

2009

Nyxoah S.A. logo

Nyxoah S.A. Employee Contacts

17 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Nyxoah S.A. Overview

FieldDetail
Legal nameNyxoah SA (société anonyme / naamloze vennootschap under Belgian law)
Former namesNone publicly disclosed
Founded2009 (founded by Robert Taub, current Chairman)
Incorporation jurisdictionBelgium
Registered office / HQRue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (per SEC Form 6-K cover, June 2026)
Primary listingEuronext Brussels — NYXH (since September 2020)
Secondary listingNasdaq Global Market — NYXH (since July 2021)
Other trading venuesStuttgart (5YI), among other German venues — unofficial secondary trading
ISINBE0974358906
CUSIPNot publicly disclosed in sources reviewed (Nasdaq line trades as ordinary shares, not ADSs)
SEC filer statusForeign private issuer; files Form 20-F (annual) and Form 6-K (current/quarterly); CIK 0001857190
Fiscal year end31 December
Employeesnot publicly disclosed in sources reviewed. Directionally, the U.S. sales organisation grew from 25 to 40 field representatives in Q1 2026, with a plan to reach 55 territories in H2 2026
AuditorNot re-verified for FY2025 in this research cycle (historically a Big Four firm's Belgian practice; confirm against the 20-F)
Market capitalisation (current)About USD 98M at USD 0.96 intraday on 19 October 2026, after a ~13% fall on the guidance cut (Stock Titan); about USD 113M at the USD 1.11 close on 16 October 2026 (Yahoo Finance)
Shares outstanding101,840,217 as of 25 August 2026, per a company share-capital notice cited by a third-party tracker; later convertible-bond share settlements may have added to this
Websitewww.nyxoah.com
Investor relationsIR@nyxoah.com — Rémi Renard, Head of IR & Corporate Communication
CEOLiam Kelly (effective 1 October 2026; former Chairman, President & CEO of Teleflex)
Interim CFOLoïc Moreau (President International; interim CFO from 2 October 2026)
ChairmanRobert Taub (founder)

The entity profiled is the same listed company identified in the request: Nyxoah SA, the Belgian parent of the Nyxoah group. The listing details supplied are current. No name change or listing migration has occurred. Since July 2021 the company has been dual-listed on Euronext Brussels and the Nasdaq Global Market, both under the ticker NYXH.

Nyxoah is a Belgian medical technology company that has built a single, differentiated therapy platform for obstructive sleep apnea (OSA). Its Genio system is a hypoglossal nerve stimulation (HGNS) implant that stimulates both branches of the hypoglossal nerve. The implant is small, leadless and battery-free, and it is powered each night by an external activation chip worn on a disposable adhesive patch under the chin. Genio has carried a CE Mark since 2019 and won U.S. FDA PMA approval on 8 August 2025. Nyxoah is therefore the first credible U.S. challenger to Inspire Medical Systems, which has held an effective monopoly in HGNS. The company's thesis rests on four features: bilateral stimulation, full-body MRI compatibility, no implanted battery that must be replaced surgically, and a potential label extension to complete concentric collapse (CCC) patients, who are contraindicated for Inspire. It remains loss-making and dependent on capital markets. Its near-term value depends on how fast U.S. adoption ramps, on reimbursement clarity, and on patent litigation with Inspire.


Company's own description

In its FY2025 Form 20-F, Nyxoah describes itself as a medical technology company focused on developing and commercialising innovative OSA treatments. It calls its lead solution, Genio, a CE-Marked, patient-centric, minimally invasive, next-generation hypoglossal neurostimulation therapy for moderate to severe OSA. The company frames OSA as the world's most common sleep-disordered breathing condition, associated with higher mortality risk and comorbidities such as cardiovascular disease, depression and stroke. It describes Genio as a first-of-its-kind HGNS device that uses bilateral stimulation to keep the airway open during sleep. (Source: Form 20-F, FY2025.)

The company began generating revenue from Genio sales in Europe in July 2020. It reports that its main sources of capital to date have been private placements, public equity offerings, debt financing and product revenue. (Source: Form 20-F, FY2025.)

Independent characterisation

Revenue componentNatureDisclosure status
Implantable stimulator + surgical kitOne-time capital-like product sale per procedure, billed to hospital / ambulatory surgery centre (ASC)—
External activation chip / charging unitOne-time device sale bundled with the system—
Disposable adhesive patchesRecurring consumable, recognised over the delivery period (deferred revenue)Partially visible via deferred revenue: €1.0M deferred in FY2025, €0.3M in Q1 2026
Services / subscription / licensingNone materialNot applicable

Nyxoah is a single-product, single-indication, implant-plus-disposables business. Its economics resemble an active implantable neuromodulation company, such as a spinal cord stimulation or cochlear implant maker, with one important difference: Genio has a recurring consumables component. Each patient needs a steady supply of disposable adhesive patches to attach the external activation chip. That creates a modest annuity tail. Under IFRS 15 this tail forces revenue deferral, because patches delivered over time are recognised over time.

Revenue model mix (analyst characterisation; not segment-disclosed):

Value-chain position: Nyxoah designs the device and controls final assembly and quality in Mont-Saint-Guibert, Belgium. In January 2023 it entered a collaboration with Cochlear Limited to transfer assets and support the set-up of a U.S. production line (Source: Q3 2025 interim report, 6-K/A). Distribution is direct in the U.S., Germany and other core European markets, and goes through distributors in the Middle East.

Customer types: The paying customers are hospitals and ASCs, which buy the system and bill payers. The clinical decision-makers are ENT/sleep surgeons, with referral flowing from sleep physicians. Reimbursement comes from Medicare (U.S. facility C-codes C8011–C8013 established February 2026), commercial insurers (CPT codes for HGNS implantation, with prior authorisation required) and European statutory systems (Germany's DRG system, the UK NHS Specialised Services Devices Programme, and others).

End market: Moderate-to-severe OSA in adults who fail or cannot tolerate positive airway pressure (PAP/CPAP) therapy. This is the "second-line" OSA market that Inspire created and still dominates.

The clinical/regulatory foundation

StudyPurposeKey outcomeStatus
BLAST OSAEuropean CE Mark studySupported CE Mark (2019)Completed
BETTER SLEEPBilateral stimulation incl. CCC patients (Australia/Europe)Supported CE Mark extension to CCC patientsCompleted
DREAM (U.S. IDE pivotal)FDA PMA supportMet primary endpoints (announced 19 March 2024); published in Journal of Clinical Sleep Medicine. Labelling reflects efficacy in both supine and non-supine positions (per Q4 2025 earnings call)Completed; PMA approved 8 August 2025
ACCCESS (U.S. pivotal, CCC)U.S. label expansion to CCC patients; FDA Breakthrough Device Designation12-month AHI responder rate 77.2% (Sher criteria, p<0.001); ODI responder rate 87.7% (p<0.001); zero device-related serious adverse events; n=47 implantedTopline 2 September 2026; full data at ISSS 15–16 October 2026; PMA supplement submitted (disclosed 19 October 2026)
BREATHE (U.S. post-approval study)FDA-mandated PASFirst patient implanted 7 September 2026Enrolling
European PMCF (NCT04031040)Long-term post-market follow-upRegistry primary completion estimate 30 October 2026Ongoing

The U.S. label covers moderate-to-severe OSA with an apnea-hypopnea index (AHI) of 15 to 65 (FDA approval, 8 August 2025). The treatment of CCC patients currently appears in the warnings section of the U.S. indications for use (company boilerplate, October 2026).

Strategy

Stated strategy (themes from the FY2025 20-F, earnings calls and the July 2026 Investor Day)

Management's strategy rests on five themes (paraphrased from company disclosures):

  1. Win in the United States. The U.S. is the centre of the growth strategy. Leadership has been "Americanised" (U.S.-based CEO from October 2026), the sales force is expanding from 40 to 55 territories in H2 2026, and the company targets high-volume HGNS accounts, with 233 active by end-Q3 2026.

  2. Differentiate on patient-centric design. Bilateral stimulation, no implanted battery, full-body MRI compatibility, upgradability without re-surgery, and efficacy regardless of sleep position.

  3. Expand the addressable population. Pursue the CCC indication in the U.S. (ACCCESS; PMA supplement filed October 2026) and grow European reimbursement country by country.

  4. Secure reimbursement. Use the Medicare C-codes (C8011–C8013) and existing commercial CPT codes. The company chose not to seek a dedicated Category I CPT code at the September 2026 CPT panel and instead supports a comprehensive coding approach for all AGNS devices led by specialty societies such as AAO-HNS.

  5. Improve unit economics. Launch the Genio 2.2 patch/activation chip in early 2027 to cut disposable costs; raise manufacturing yields and overhead absorption; take gross margin from about 60% to the mid-60s and higher.

Initiatives in the last 24 months

InitiativeDateDescriptionStatus
U.S. commercial launchAugust 2025 onwardDirect sales, surgeon training, account activation, prior-authorisation supportOngoing; 342 surgeons trained, 233 accounts
Sales force expansionQ1 2026 / H2 2026+15 reps and 3 sales directors in Q1 2026 (40 reps); expansion to 55 territories in H2 2026Under way; drives Q4 2026 opex step-up
ACCCESS CCC programme2024–2026U.S. pivotal in CCC under Breakthrough Device DesignationEndpoints met; PMA supplement submitted October 2026
BREATHE post-approval studySeptember 2026FDA-required U.S. PASFirst patient implanted
Genio 2.2Target early 2027Next-gen disposable patch and activation chip; cost reductionIn development
Reimbursement engagement2,026CMS C-codes (Feb 2026); proposed 2027 OPPS (+12%) and ASC (+15%) increases for the Genio procedureFinal 2027 rule expected around November 2026
Leadership transitionJune–October 2026U.S.-based CEOCompleted (Kelly)
RecapitalisationJune 2026USD 95M equity plus USD 15M EIB trancheCompleted
Intellectual property enforcementSeptember–December 2025Countersuit in Delaware; UPC actions in MunichOngoing
International expansion2024–2025UK (NHS SSDP), Middle East, NetherlandsCompleted entries

Sustainability/ESG commitments: no quantified ESG targets were found in the sources reviewed.

Cost programmes: none announced. The company is in an investment phase, with opex guided up to €99–102M in FY2026.

Management guidance and medium-term targets

MetricGuidanceDate issuedStatus
FY2026 global net revenue€33–35M19 October 2026Lowered from €36–40M (issued with Q4 2025 results / Q1 2026; reaffirmed in August and on 21 September 2026)
FY2026 gross margin60–62%Q1 2026; reaffirmed 21 September 2026Current; H2 2026 expected at 63–64%
FY2026 total operating expenses€99–102MReaffirmed 21 September 2026 (raised at Q2 per Stock Titan's Q2 summary)Current
Q4 2026 U.S. growthImproving sequential U.S. growth vs Q319 October 2026Current
Implied Q4 2026 revenue€9.7–11.7M (analyst derivation: guidance less €23.3M nine-month revenue)—Derived
Medium-term targets (revenue, profitability timing)A path to profitability was discussed at the July 2026 Investor Day8 July 2026Not publicly verified

Products & Services

Nyxoah sells a single product family. The catalog below breaks Genio into its components and generations.

Genio system (current commercial generation)

AttributeDetail
ProductGenio® hypoglossal nerve stimulation system
Indication (EU)Moderate to severe OSA, including CCC patients (CE Mark extension after BETTER SLEEP)
Indication (U.S.)Moderate to severe OSA, AHI 15–65 (FDA PMA, 8 August 2025); CCC currently in label warnings; PMA supplement for CCC filed October 2026
MechanismBilateral stimulation of both hypoglossal nerve branches to protrude the tongue and keep the upper airway open during sleep
ImplantSmall, leadless, battery-free neurostimulator placed under the chin through a single submental incision; electrodes contact both hypoglossal nerve branches
PowerExternal activation chip on a disposable adhesive patch worn nightly; energy transferred wirelessly
Key claimed advantagesNo implanted battery (no battery-replacement surgery); full-body MRI compatibility; upgradable external electronics without re-surgery; bilateral stimulation; single incision; efficacy in supine and non-supine positions per U.S. labelling
ComponentsImplantable stimulator; activation chip; charging unit; disposable adhesive patches; physician programming tools
Target customerENT/sleep surgeons at high-volume HGNS centres (hospitals and ASCs); patients intolerant of CPAP
LaunchEU 2019 (CE Mark), first revenue July 2020; U.S. August 2025
Pricing modelPer-procedure system price plus recurring disposables; list prices not publicly disclosed. U.S. Medicare hospital outpatient payment for C8011 is USD 31,526 in 2026, with a CMS proposal of USD 35,414 for 2027 (+12%); the proposed ASC increase is about 15%
VersioningThe current generation is referred to as Genio 2.1 in company materials (per prior disclosures); next generation below

Genio 2.2 (next-generation disposable patch / activation chip — in development)

AttributeDetail
DescriptionNext-generation disposable patch and activation chip
RationaleBetter patient experience and a significant cut in disposable patch cost, which should lift gross margin
TimingLaunch expected in early 2027 (per the then-CFO on the Q4 2025 earnings call, 19 March 2026)
Financial impactManagement guided a larger gross-margin step-up in early 2027 from Genio 2.2

Pipeline indications / label expansions

ProgrammeStatusCommercial relevance
CCC indication (U.S.)ACCCESS met endpoints; PMA supplement submitted under Breakthrough Device Designation (19 October 2026)Opens patients who cannot receive Inspire therapy because of CCC on drug-induced sleep endoscopy
Long-term outcomes (BREATHE, PMCF)OngoingSupports payer coverage and durability claims

Services

Nyxoah offers no stand-alone service lines. Its surgeon training, account activation and patient-access support (help with prior authorisation) are commercial enablement activities, not revenue-generating services.

Financial Narrative

Data quality statement

FY2023–FY2025 figures come from the company's annual results releases and the FY2025 20-F. Cells left blank were not publicly verified during this research and are not estimated. EBITDA is not reported by the company.

Income statement

Sources: FY2024 results release (13 March 2025): revenue €4.5M after €0.6M deferral (underlying €5.1M); COGS €1.5M; FY2023 COGS €1.7M and gross margin 62%; R&D €34.3M vs €26.7M; SG&A €28.5M vs €21.7M; operating loss €58.8M vs €45.1M; total comprehensive loss €58.459M vs €43.251M. FY2025 results release (19 March 2026) and 20-F: gross revenue €11.0M, net revenue €10.0M, operating loss €83.5M. The FY2025 net loss of about €90.1M appears in the 20-F (rounded to €90.0M) and on Stock Analysis (€90.09M, +52.1% vs FY2024), which implies a FY2024 net loss of about €59.2M.

EPS, dividends, EBITDA:

Basic and diluted EPS are identical for a loss-making company. Yahoo Finance shows trailing-twelve-month EPS of about USD -2.56 as of October 2026 (aggregator). EBITDA is not reported and not computed. It is deeply negative, roughly approximated by the operating loss plus D&A.

Margin profile

FY2024 gross margin is derived as (4.5 − 1.5)/4.5. The company reported a Q4 2024 gross margin of 73%. Q1 2025 was 62% and Q2 2025 was 63% (6-K).

Revenue CAGR: FY2021–FY2025 ≈ 88% per year (€0.8M → €10.0M). FY2023–FY2025 ≈ 52% per year. Both are computed from the table above. The base is small, which inflates these rates.

Quarterly bridge — the U.S. launch inflection

Sources: Q1 2025, H1 2025 and 9M 2025 interim reports (6-K); Q4/FY2025 release; Q1 2026 and Q2 2026 releases; preliminary Q3 2026 release (19 October 2026, unaudited). Q3 2025 global revenue is derived as 9M €4.4M minus H1 €2.4M. U.S. Q3 2025 revenue was €231,000. Q2 2025 net loss is derived as H1 €43.0M minus Q1 €22.4M. Q3 2025 net loss is derived as 9M €66.6M minus H1 €43.0M. Q2 2026 net loss is derived as H1 €48.9M minus Q1 €15.9M. U.S. Q4 2025 is €3.4M per the Q1 2026 call; the preliminary release had indicated about €3.5M. International figures are derived. The Q3 2026 split is preliminary.

Commentary. The income statement has two regimes. From 2021 to mid-2025 Nyxoah was a European-only business with flat revenue of about €1–1.3M per quarter. Spending rose sharply as it funded DREAM, the PMA submission and U.S. launch preparation: operating loss widened from €45.1M (FY2023) to €58.8M (FY2024). After the FDA approval in August 2025, U.S. revenue went from zero to €6.7M per quarter within five quarters. Sequential U.S. growth was 25% in Q1 2026, 22% in Q2 and 29% in Q3. Even so, the quarterly operating loss has stayed stuck at about €20M. Commercial build-out (SG&A up from about €11–12M to about €15.5M per quarter) has absorbed every incremental euro of gross profit.

Gross margin fell from the low 60s to 57% in Q1 2026. Management blamed the higher U.S. revenue mix and production yields, and guided a recovery to 63–64% in H2 2026 and a further step-up with Genio 2.2 in 2027. FY2026 operating expense guidance of €99–102M (reaffirmed 21 September 2026) implies a sharp Q4 step-up as the U.S. sales force grows from 40 to 55 territories.

The FY2025 net loss of €90.1M was worse than the operating loss of €83.5M. The gap came from negative financial results: USD depreciation, interest on the EIB loan, and fair-value movements on the EIB synthetic warrants and, later, the convertible bond. In H1 2026 the net financial result was a €7.0M charge. Of that, €5.4M came from fair-value losses on the convertible bond and synthetic warrant liabilities, and €1.5M from amortisation of the day-one loss on the convertible.

Balance sheet

Sources: FY2024 release (cash and financial assets €85.6M vs €57.7M; cash and equivalents €34.186M); FY2025 release and 20-F (cash €30.0M, financial assets €18.0M, long-term debt €19.0M, accumulated deficit €306.0M — these appear rounded in the 20-F overview text). FY2024 financial assets are derived. Nyxoah has made no acquisitions, so it carries no acquisition goodwill. Capitalised development costs are the main intangible and were not quantified here.

Debt instruments outstanding (as of mid-October 2026, from filings):

Net debt / net cash (analyst derivation, nominal values): At 31 December 2025, cash and financial assets of €48.0M against nominal borrowings of about €32.5M (EIB €10.0M plus convertible €22.5M) implied net cash of about €15.5M. At 30 June 2026, cash of €97.8M against about €42M of nominal debt (including Tranche B and after partial convertible amortisation) implied net cash of roughly €55M. These are derivations, not company-reported metrics. IFRS carrying values differ because the convertible and warrants are carried at fair value.

Cash flow

Q3 2026 burn was about €20.8M (€97.8M → €77.0M; preliminary). Annualised, that is about €80–85M, before the guided Q4 opex step-up.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (As Reported) Overview

Segment (as reported)ContentsProducts

Single segment — OSA neuromodulation

All revenue, cost and assets

Genio system (implant, activation chip, disposable patches, programming/charging equipment)

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Segment net revenue (EUR Mn)

4.34.510.0

YoY growth (%)

395122

Contribution to total revenue (%)

100100100

Operating loss (EUR Mn)

-45.1-58.8-83.5

Revenue by Segment and Revenue by Segment (%)

MetricFY2023FY2024FY2025

U.S. net revenue (EUR Mn)

0.00.03.7

International net revenue (EUR Mn)

4.34.56.3

U.S. share of total (%)

0037

Group Entities

EntityJurisdictionFunction

Nyxoah SA

Belgium

Parent, HQ, manufacturing, R&D, listed entity

Nyxoah, Inc.

United States

U.S. commercial operations; co-defendant in Inspire litigation

Other subsidiaries (Israel R&D, Australia clinical, European sales entities)

Various

—

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Net revenue (EUR Mn)

0.83.14.34.510.0

Gross revenue before patch deferral (EUR Mn)

——4.35.111.0

Cost of goods sold (EUR Mn)

——1.71.5—

Gross profit (EUR Mn)

——2.73.0—

R&D expense (EUR Mn)

——26.734.3—

SG&A expense (EUR Mn)

——21.728.5—

Operating income (EUR Mn)

——-45.1-58.8-83.5

Net income (EUR Mn)

——-43.2-59.2-90.1

Total comprehensive loss (EUR Mn)

——-43.3-58.5—

Financial Analysis

MetricFY2021FY2022FY2023FY2024FY2025

Dividends per share (EUR)

00000

Margin Analysis (%)

MetricFY2023FY2024FY2025

Gross margin (%)

6267—

Operating margin (%)

-1,049-1,307-835

Net margin (%)

-1,005-1,316-901

Income Statement and Margin Analysis (%)

MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026

Global net revenue (EUR Mn)

1.11.32.05.66.47.79.2

U.S. net revenue (EUR Mn)

0.00.00.23.44.35.26.7

International net revenue (EUR Mn)

1.11.31.82.22.12.52.5

Gross margin (%)

6263——5760—

R&D expense (EUR Mn)

9.010.1—10.98.89.5—

SG&A expense (EUR Mn)

12.410.7—12.515.415.6—

Operating loss (EUR Mn)

-20.6-19.9—-18.6-20.5-20.6—

Net loss (EUR Mn)

-22.4-20.6-23.6—-15.9-33.0—

Cash + financial assets, period end (EUR Mn)

63.043.022.548.025.997.877.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Financials

MetricFY2023FY2024FY2025

Cash + current financial assets (EUR Mn)

57.785.648.0

Cash & cash equivalents (EUR Mn)

—34.230.0

Financial assets / term deposits (EUR Mn)

—51.418.0

Long-term debt (EUR Mn)

——19.0

Accumulated deficit (EUR Mn)

——306.0

Capital Instruments

InstrumentCounterpartyPrincipalTermsStatus

EIB venture loan — Tranche A

European Investment Bank

€10.0M

Part of €37.5M facility (July 2024); InvestEU-backed; no revenue or liquidity covenants; 20-year synthetic warrants granted to EIB

Drawn (2024)

EIB venture loan — Tranche B

European Investment Bank

€13.75M (received as about €13.8M / USD 15M)

Same facility

Drawn June 2026

EIB venture loan — Tranche C

European Investment Bank

€13.75M

Subject to conditions

Undrawn as of last disclosure

Convertible bonds — Tranche 1

Entity managed by Heights Capital Management

€22.5M nominal (225 bonds × €100k)

6.5% coupon; 3-year amortising to 2028; quarterly principal of €8,500 per bond, settleable in shares under certain conditions; senior unsecured

Issued 18 December 2025; amortising, partly settled in shares (e.g., 1,767,402 shares issued around August 2026, per a third-party tracker of company notices)

Convertible bonds — Tranche 2

HCM

Up to €22.5M

Optional; substantially the same terms

Drawdown not confirmed in sources reviewed

Balance Sheet

MetricFY2023FY2024FY2025

Change in cash + financial assets (EUR Mn)

—27.9-37.6

Equity raised, gross (EUR Mn)

—48.517.0

Debt raised, gross (EUR Mn)

—10.022.5

Dividends paid (EUR Mn)

000

Share buybacks (EUR Mn)

000

Financial Analysis (FY2025 value)

RatioFY2025 valueComment

ROE

NM (negative)

—

ROA

NM (negative)

—

ROIC

NM (negative)

—

Current ratio

Not computed

Liquidity dominated by cash/term deposits

Debt / equity

Not computed

—

Asset turnover

Very low

Revenue €10.0M

Cash runway (analyst view)

About 3–4 quarters at the Q3 2026 burn rate from €77.0M, before any Tranche C/convertible Tranche 2 drawdown and before revenue growth

Implies a likely return to capital markets during 2027 unless burn falls

Revenue by Region and Region Margins & Growth (%)

RegionFY2023FY2024FY2025

United States net revenue (EUR Mn)

0.00.03.7

International (Europe + Middle East) net revenue (EUR Mn)

4.34.56.3

Total net revenue (EUR Mn)

4.34.510.0

International YoY growth (%)

39540

Revenue by Region

RegionH1 2025H1 2026Q3 2026 (prelim.)

United States (EUR Mn)

0.09.56.7

International (EUR Mn)

2.44.52.5

Total (EUR Mn)

2.414.09.2

Country / Market Details

Country / marketFirst revenueChannelNotes

Germany

2,020

Direct

Largest European market; break-even reached H1 2026; ResMed Germany partnership

Other initial EU markets

2020–2023

Direct

Specific early markets per prior filings

Austria, Spain, Italy

Disclosed as revenue-generating by 2025

Direct/hybrid

Reimbursement dossiers pending in additional countries

United Kingdom

Q4 2024

NHS SSDP

—

UAE (Dubai)

Q1 2025

Distributor

First Middle East market

Kuwait, Abu Dhabi

Q2 2025

Distributor

—

Netherlands

Q4 2025

Direct

—

United States

Q3 2025

Direct

233 active high-volume accounts and 342 trained surgeons by end-Q3 2026

Share Price & Returns

Reference pointPrice (USD)DateSource

Nasdaq IPO

30.00

2 July 2021

MarketBeat

Start of 2025

8.00

1 January 2025

MarketBeat

FDA approval

about 7.28

8 August 2025

MobiHealthNews

October 2025

6.10

8 October 2025

MarketBeat

52-week high (to early October 2026)

6.875

Q4 2025

Stock Analysis

May 2026

2.99

1 May 2026

Fintel

Offering price

1.72

5 June 2026

Company

Pre-Q2 results

1.43

29 July 2026

MarketBeat

Early October 2026

1.36

2 October 2026

Stock Analysis

Last close before guidance cut

1.11

16 October 2026

Yahoo Finance

Intraday after guidance cut

about 0.96

19 October 2026

Stock Titan (15-minute delayed)

Return metric

NYXH

Basis

—

1-year return (%)

about -84

From about USD 6.10 (October 2025) to about USD 0.96 (analyst derivation)

—

3-year return (%)

Not computed

——

5-year / since Nasdaq IPO (%)

about -97

From USD 30.00 (July 2021) to about USD 0.96

—

Valuation Multiples

MultipleNYXHComment

EV/Sales (FY2026E guidance midpoint €34M ≈ USD 39M)

about 1.4x

Market cap about USD 98M, less net cash of roughly USD 40–50M (Q3 2026 cash €77.0M less about €40M nominal debt), gives EV of about USD 50–60M. Analyst derivation; very approximate

P/B

about 1.5x (aggregator, mid-2026; pre-raise book)

Gurufocus; stale

Analyst Ratings & Targets

BrokerRatingPrice target (USD)Date

Cantor Fitzgerald (Sarah James)

Overweight

6.00 (from 11.00)

17 August 2026

Piper Sandler (Adam Maeder)

Overweight

6.00 (from 7.00; earlier cut from 9.00 to 7.00 on 13 May 2026)

Post-Q2 2026

Oppenheimer

Outperform

4.00 (from 13.00)

August 2026

Stifel

Hold (downgraded from Buy earlier)

3.00 (from 5.00)

17 June 2026

Baird

Neutral

2.31 (from 2.85; earlier 4.00 → 2.85 on 9 July 2026)

Post-Q2 2026

Consensus

"Buy" (Stock Analysis, 4 analysts) / "Hold" (MarketBeat)

about 4.2–4.4

October 2026 (aggregators)

Capital Markets

ItemStatus

Dividend history

None paid; no dividend expected (accumulated deficit €306M at end-2025)

Dividend policy

Retain all earnings to fund operations

Credit ratings (Moody's / S&P / Fitch)

Not rated

Shares outstanding

101,840,217 (25 August 2026) vs 34,360,390 earlier in the cycle (TipRanks notice) and about 37.4M (2025)

Share capital

€7,073,687.00 (latest notice per aggregator)

Capital Instruments — HCM convertible Tranche 1

InstrumentPrincipalMaturityAmortisation

HCM convertible Tranche 1

€22.5M nominal (amortising)

December 2028

Quarterly €1.9125M (€8,500 × 225 bonds), final €1.4625M; may be share-settled

EIB Tranche A

€10.0M

——

EIB Tranche B

€13.75M

As above

—

EIB Tranche C

€13.75M (undrawn)

—

Conditional

Analyst Conclusions

Management guidance (current)

ItemGuidance
FY2026 net revenue€33–35M (lowered 19 October 2026)
Q4 2026 U.S. growthSequential growth expected to improve vs Q3's 29%
FY2026 gross margin60–62%
FY2026 operating expenses€99–102M
2027 margin driverGenio 2.2 disposable patch launch (early 2027)
RegulatoryFDA review of the CCC PMA supplement (Breakthrough designation)

Consensus growth expectations: Formal post-cut consensus was not available at the time of writing. Pre-cut aggregator data showed multi-year revenue CAGR expectations above 100% from a small base (AlphaSpread), which are now likely to be revised down.

Bull case (3 arguments)

  1. The adoption curve is intact; only the slope was mis-forecast. U.S. revenue grew 29% sequentially in Q3 2026. Accounts rose from 180 to 233 in one quarter, and 447 patients are in prior authorisation. Each newly activated account should deepen utilisation over 12–24 months. The guidance cut reflects timing, not demand.

  2. A CCC approval would create a defensible niche. With a 77.2% AHI responder rate and zero device-related SAEs in a population Inspire cannot treat, a CCC label would give Nyxoah exclusive access to a meaningful slice of DISE-screened patients. It would also strengthen the wider "choice" narrative.

  3. Valuation is near cash-adjusted distress. At about USD 100M market capitalisation, with roughly €77M of gross cash and a run-rate of about €37M+ in annual revenue, EV/Sales is roughly 1–1.5x. That is extremely low for a growing, FDA-approved implant platform. Reimbursement increases (+12–15% in 2027), Genio 2.2 margin expansion and a seasoned CEO from Teleflex could prompt a re-rating or attract strategic interest.

Bear case (3 arguments)

  1. Unit economics and funding do not yet work. Quarterly operating losses of about €20M on €7–9M revenue, gross margin of about 60%, and opex guided to rise imply roughly €80M+ of annual burn. Cash of €77.0M implies another dilutive raise within about 12 months, at a share price below USD 1.

  2. Litigation could prove existential. The IPRs were denied, the Markman hearing is imminent, and a December 2027 jury trial is scheduled. An adverse outcome against an incumbent with far greater resources could bring an injunction or royalties that cripple U.S. economics.

  3. The category itself is under pressure. Inspire's U.S. revenue is declining in 2026 on coding and prior-authorisation disruption. GLP-1/GIP drugs could shrink the surgical pool. Nyxoah's external wearable may cap patient preference. The company has cut guidance and changed CEO and CFO within months, which hurts management credibility.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhy it matters
29 October 2026Markman hearing, Inspire v. Nyxoah (consolidated)Claim scope shapes infringement and validity risk
About November 2026CMS final 2027 OPPS/ASC ruleConfirms the proposed +12% / +15% payment increases
5 November 2026Full Q3 2026 resultsGross margin, opex trajectory, cash burn detail, new CEO's priorities
Q4 2026Delivery of €9.7–11.7M implied Q4 revenueTests the revised guidance
Late 2026 – 2027Nasdaq minimum bid price complianceA deficiency notice is possible if shares stay below USD 1.00
H1 2027FDA decision on the CCC PMA supplementLabel expansion
Early 2027Genio 2.2 launchGross-margin step-up
2,027Financing (EIB Tranche C, convertible Tranche 2, equity)Dilution and runway
OngoingAccount productivity (revenue per active account), surgeon training, PA approval rateLeading indicators of the ramp
OngoingUPC Munich proceedings vs InspireEuropean IP leverage
OngoingAGNS CPT coding outcome (AMA/specialty societies)Physician payment clarity

Concluding analyst verdict

Nyxoah has done the hardest thing a medical device start-up can do: it has won FDA approval for a differentiated implant and launched it against an entrenched incumbent. The clinical case is sound. DREAM supported approval, and ACCCESS has now produced a 77.2% responder rate with no device-related serious adverse events in CCC patients, a population Inspire cannot treat. The commercial leading indicators are moving the right way. Active U.S. accounts rose from 91 to 233 and trained surgeons from 207 to 342 within two quarters, and U.S. revenue grew 29% sequentially in Q3 2026.

The investment debate, however, is no longer about whether Genio works. It is about time and money. The October 2026 guidance cut shows that utilisation per account is building more slowly than management modelled. Meanwhile the cost base is still rising toward €99–102M a year and gross margin sits near 60% until Genio 2.2 arrives in 2027. With €77.0M of cash and roughly €20M of quarterly burn, Nyxoah will probably need more capital in 2027, and the share price below USD 1 makes any raise highly dilutive. The Inspire litigation is a binary overlay: the Markman hearing on 29 October 2026 and the December 2027 trial could either neutralise or seriously impair the U.S. franchise.

Liam Kelly's appointment is the most important qualitative positive. He brings proven scaling discipline from Teleflex, but his first act was resetting expectations, and he has no permanent CFO. Our synthesis: Nyxoah is a high-risk, high-optionality turnaround of a sound technology. Its valuation now discounts significant failure risk. Investors with tolerance for dilution and litigation risk may find asymmetric upside, from a CCC approval, reimbursement increases, margin expansion or strategic interest. More conservative investors should wait for evidence of operating leverage, ideally a quarterly operating loss falling below €15M, and for clarity on claim construction before committing capital.


Data caveats: Preliminary Q3 2026 figures are unaudited and subject to revision. Aggregator data (share counts, ownership, market capitalisation, consensus) varies between sources and should be checked against company transparency notifications and SEC filings. Blank cells in multi-year tables indicate data not publicly verified in this research cycle, not zero values. Items marked "analyst derivation" are arithmetic computations from disclosed figures, not company-reported metrics.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation

Liam Kelly

Chief Executive Officer

Since 1 October 2026

Chairman (from May 2020), President and CEO (from January 2018) of Teleflex until January 2026; joined Teleflex in 2009, roles included President EMEA, President International, President Americas, COO

Not yet disclosed (appointment post-dates the FY2025 20-F)

Loïc Moreau

President International and Interim CFO

Joined 2022 as CFO; President International since 2024; interim CFO from 2 October 2026

Corporate finance background

—

Olivier Taelman

Former CEO (2019–30 September 2026)

About 7 years

Led Nyxoah from clinical stage through FDA approval

—

John Landry

Former CFO

Left 2 October 2026

Departed for another opportunity

—

Rémi Renard

Head of IR & Corporate Communication

———

Board of Directors

DirectorRoleIndependenceBackground

Robert Taub

Chairman; founder

Non-independent (founder; related party for the June 2026 offering)

Co-founded and co-managed Octapharma for 12 years; founded Omrix Biopharmaceuticals (Nasdaq IPO, acquired by J&J)

Kevin Rakin

Director (since June 2016)

Treated as related party for the June 2026 offering (participation via controlled entities)

Co-founder of HighCape Partners; former Chairman/CEO of Advanced BioHealing (sold to Shire, 2011); co-founder/CEO of Genaissance Pharmaceuticals; MBA Columbia; degrees from the University of Cape Town

Jürgen Hambrecht

Director

Treated as related party for the June 2026 offering

About 45 years at BASF, finally Chairman of its Supervisory Board 2014–2020; Chairman of Trumpf's Supervisory Board

Rita Johnson-Mills

Independent director; chairs the Nominating & Governance Committee

Independent

Former market CEO at Centene and UnitedHealthcare; former CMS Medicaid managed care oversight; boards incl. Owens & Minor; NACD Directorship 100 honoree (2025)

Virginia Kirby

Independent director

Independent

Member of the independent committee that reviewed the June 2026 related-party offering participation

Wildman Ventures, LLC (represented by Daniel Wildman)

Independent director

Independent

Long J&J career (Digital Surgery Strategy, DePuy Synthes Spine, Ethicon Biosurgery); Chairman of Progenerative Medical; UroGen Pharma board

Olivier Taelman

Executive director (historical)

Non-independent

Board status after stepping down as CEO not confirmed

Liam Kelly

——

Board appointment not confirmed in sources reviewed

Board & Management Changes

DateChangeContext
2024

Loïc Moreau moves from CFO to President International

U.S.-focused finance leadership brought in pre-launch

4 June 2026

Board launches search for a U.S.-based CEO; Taelman to remain through the transition

Positioned as accelerating the U.S. launch; announced alongside the USD 95M offering

21 September 2026

CFO John Landry resigns effective 2 October 2026; Moreau appointed interim CFO; FY2026 guidance reaffirmed

Second senior departure within four months

28 September 2026

Liam Kelly appointed CEO effective 1 October 2026

Highly credentialed U.S. medtech CEO

19 October 2026

Kelly's first public communication is a guidance cut

Kelly attributed the slower ramp to typical new-technology adoption curves

Major Shareholders

HolderStakeSource / dateComment

Insiders (aggregate)

About 17% (pre-June 2026 offering)

MarketBeat (2025)

Founder- and board-linked holdings; insiders participated in the June 2026 offering, so the current percentage may differ

Vestal Point Capital LP

About 6.8% (2025)

MarketBeat (April 2025)

Holding may have changed; a Schedule 13G/A was filed 14 August 2026 (filer not confirmed here)

Competitive Landscape

Key Competitors

#CompetitorCategoryProduct(s)Relative positioning vs Nyxoah
1

Inspire Medical Systems (NYSE: INSP)

HGNS — direct

Inspire V (5th generation), Inspire IV

Dominant incumbent with about USD 0.8–0.9bn revenue; vast installed base and surgeon network; unilateral stimulation with implanted battery; CCC contraindicated. Facing its own 2026 coding/reimbursement disruption

2

LivaNova (aura6000 / ex-ImThera)

HGNS — direct (pipeline)

aura6000 proximal HGNS (OSPREY trial)

Pursuing U.S. approval per 2026 industry commentary; potential third entrant

3

ResMed

PAP — first-line therapy (also a Nyxoah partner)

AirSense CPAP devices, masks, digital health

First-line standard of care; feeds the CPAP-failure pool HGNS addresses

4

Philips Respironics

PAP

DreamStation

Diminished U.S. presence after its device recall; still relevant outside the U.S.

5

Fisher & Paykel Healthcare

PAP interfaces

Masks, humidification

PAP ecosystem

6

Eli Lilly

Pharmacological

Zepbound (tirzepatide), FDA-approved for moderate-to-severe OSA in adults with obesity (December 2024)

Structural threat: weight loss lowers AHI and could shrink or delay the HGNS-eligible population; also possibly complementary (bringing BMI into HGNS range)

7

Apnimed

Pharmacological (pipeline)

AD109 (oral combination)

—
8

Oral appliance makers (e.g., SomnoMed, ProSomnus)

Mandibular advancement devices

Custom oral appliances

Alternative for mild-to-moderate OSA

9

Vivos Therapeutics

Oral appliance / airway remodelling

DNA/mRNA appliances

Niche alternative

10

Surgical alternatives (UPPP, MMA, TORS)

Procedures

Soft-tissue and skeletal surgery

Legacy alternatives with higher morbidity

Peer Comparison FY2026

MetricNyxoahInspire Medical

Latest annual revenue

€10.0M (FY2025)

About USD 0.91bn (FY2025, implied from FY2026 initial guidance of USD 1,003–1,013M at +10–11%)

Current-year outlook

€33–35M FY2026

USD 835–875M FY2026 (raised in August 2026 from 825–875; cut in May from about 1,003–1,013)

Growth

+122% FY2025; FY2026 guide implies about +230–250%

Q2 2026 revenue -7.6% YoY; Q3 2026 guided -8% to -10% YoY

Gross margin

60% (Q2 2026)

—

Operating margin

Deeply negative (Q2 2026 operating loss €20.6M on €7.7M revenue)

Adjusted operating margin guided 4–6% FY2026

R&D intensity

More than 100% of revenue

—

Company Snapshot

$11.3M

Revenue

$98M

Market Cap

2009

Founded

Mont-Saint-Guibert, Belgium

Headquarters

SWOT Analysis

Strengths

  • FDA approval secured. PMA granted 8 August 2025 for AHI 15–65, ending years of regulatory risk.
  • Differentiated architecture. Battery-free, leadless, bilateral, full-body MRI compatible, and upgradable without re-surgery. These are explicit claims in company disclosures and litigation statements (September 2025).
  • Strong CCC data. ACCCESS 12-month AHI responder rate of 77.2% and ODI responder rate of 87.7%, with zero device-related SAEs (2 September 2026).
  • Fast U.S. adoption metrics. U.S. revenue rose from €0.2M (Q3 2025) to €6.7M (Q3 2026). Accounts grew from 91 to 233 and trained surgeons from 207 to 342 between Q1 and Q3 2026.
  • Recapitalised. About USD 110M raised in June 2026; cash and financial assets were €77.0M at 30 September 2026.
  • Experienced new CEO. Liam Kelly ran Teleflex, a multi-billion-dollar medtech company, as CEO from 2018 to January 2026.
  • Committed insider and strategic base. Founder Robert Taub, Jürgen Hambrecht and Kevin Rakin took part in the June 2026 raise; ResMed and Cochlear are strategic partners.

Weaknesses

  • Single product, single indication. 100% of revenue comes from Genio.
  • Heavy losses. FY2025 net loss of €90.1M on €10.0M revenue; quarterly operating loss stuck at about €20M through Q2 2026.
  • Gross margin below peer norms. 57% in Q1 2026 and 60% in Q2 2026, versus implant-device norms of 70–80%+; Genio 2.2 relief is not due until 2027.
  • Forecasting credibility. FY2026 revenue guidance cut from €36–40M to €33–35M within three weeks of being reaffirmed (21 September → 19 October 2026).
  • Management turnover. CEO change (October 2026) and CFO departure (October 2026), with an interim CFO in place.
  • Dilution history. June 2026 equity priced at USD 1.72, against a USD 30 Nasdaq IPO price (2021) and €4.00 in November 2025. Share count more than doubled in 2026.
  • Wearable dependency. The nightly external patch is a usability trade-off compared with fully implanted competitors (analyst assessment; not quantified by the company).

Opportunities

  • CCC label expansion in the U.S. PMA supplement submitted under Breakthrough designation (October 2026). This opens a segment Inspire is contraindicated for.
  • Reimbursement tailwinds. CMS proposed raising C8011 from USD 31,526 to USD 35,414 (+12%) for 2027, plus about a 15% ASC increase.
  • Incumbent disruption. Inspire's Q2 2026 revenue fell 7.6% and it guided Q3 down 8–10%, which creates openings for share gains.
  • Genio 2.2 margin lever. Management expects a significant cut in disposable patch cost from early 2027.
  • International breadth. Germany break-even in H1 2026; new markets (UK, Middle East, Netherlands) with more reimbursement dossiers pending.
  • Strategic optionality. A sub-USD 150M market capitalisation for an FDA-approved differentiated platform could attract acquirers (speculative; no reported interest).

Threats

  • Inspire patent litigation. Claim construction 29 October 2026; jury trial 13 December 2027; IPRs denied 14 April 2026. A loss could bring an injunction or royalties.
  • Pharmacological substitution. Tirzepatide approved for OSA (December 2024); more drugs in development.
  • Coding uncertainty. Industry-wide HGNS coding changes cut Inspire's 2026 outlook by about USD 130–180M at the midpoint; Nyxoah faces the same payer environment.
  • Third entrant. LivaNova aura6000 is pursuing approval.
  • Funding risk. At a quarterly burn of about €20M+, current cash lasts into roughly 2027 (analyst derivation). Further raises at depressed prices would mean more dilution.
  • Nasdaq listing compliance. Shares below USD 1.00 (intraday about USD 0.96 on 19 October 2026). A sustained 30-business-day close below USD 1.00 would trigger a Nasdaq minimum bid price deficiency notice (analyst flag; no notice reported as of this date).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Q2 2025First revenue in Kuwait and Abu DhabiMiddle East expansion
30 May 2025Inspire files infringement suit in D. Del. (1:25-cv-00667), calling Nyxoah a self-described "smart follower"Litigation overhang begins before U.S. launch
July 2025Preliminary Q2 2025 results; term debt facility with €27.5M remaining availability disclosedLiquidity visibility
8 August 2025FDA PMA approval (AHI 15–65); shares around USD 7.28Transformational event
August 2025U.S. commercial launch starts immediatelyFirst U.S. revenue in Q3 2025 (€231k)
15 September 2025Nyxoah sues Inspire over three U.S. patentsCounter-leverage
13 October 2025Board issues 760,000 warrantsIncentive alignment
13 November 2025Q3 2025 results; €17.0M placement at €4.00; up to €45M HCM convertible facilityFinancing at falling prices
1 December 2025Two UPC infringement actions against Inspire (Munich)European IP front
18–19 December 2025€22.5M first convertible tranche issuedLiquidity
Q4 2025First revenue in the NetherlandsEuropean expansion
January 2026Preliminary FY2025: net revenue about €10.0M (+122%); cash about €47.9MLaunch traction
February 2026CMS creates interim C-codes C8011–C8013 for externally powered AGNSU.S. facility billing clarity
16 February 2026Inspire withdraws objections to a court ruling in the litigation (procedural)Litigation procedure
19 March 2026FY2025 results: Q4 net revenue €5.6M (+347% YoY); FY operating loss €83.5M; Q1/Q2 2026 guided to +25% sequential eachGuidance framework
23 March 2026Inspire moves to dismiss certain of Nyxoah's claims; Nyxoah amendsLitigation
26 March 2026FY2025 Form 20-F filedAnnual disclosure
14 April 2026PTAB denies Nyxoah's IPR petitionsLitigation setback
12 May 2026Q1 2026: net revenue €6.4M (+13% q/q); U.S. €4.3M (+25%); 91 active accounts; gross margin 57%; cash €25.9M; FY2026 revenue €36–40MLiquidity critically low before the raise
15 May 2026Delaware court consolidates Inspire v. Nyxoah and Nyxoah v. InspireLitigation streamlined
4 June 2026CEO transition process announced; offering launchedLeadership and funding reset
5–10 June 2026USD 95M offering at USD 1.72 priced and closedRemoves going-concern pressure; heavy dilution
15 June 2026Prix Galien UK 2026 awardRecognition
17 June 2026EIB Tranche B: USD 15M receivedTotal June raise about USD 110M
7 July 2026Preliminary Q2: €7.7M revenue; CMS proposes 12% OPPS increase for C8011Reimbursement tailwind
8 July 2026Investor & Analyst Day, New YorkStrategy update; Baird cuts target to USD 2.85 the next day
5 August 2026Q2 2026: revenue €7.7M; U.S. €5.2M; gross margin 60%; operating loss €20.6M; 180 accounts; cash €97.8M; opex guidance raised; company decides not to seek a dedicated CPT code at the September panelMixed reception; shares -7% the next day
17 August 2026Cantor cuts target to USD 6 from 11 (Overweight maintained); Oppenheimer cuts to USD 4 from 13Sell-side derating
2 September 2026ACCCESS meets endpoints (AHI responder 77.2%; ODI 87.7%; zero device-related SAEs)Label-expansion catalyst
7 September 2026First patient in the BREATHE post-approval studyRegulatory compliance
21 September 2026CFO Landry departs; Moreau interim; guidance reaffirmedManagement churn
28 September 2026Liam Kelly named CEO (effective 1 October)Experienced operator
15–16 October 2026Full 12-month ACCCESS data presented at ISSS, Los AngelesScientific validation
19 October 2026Preliminary Q3: €9.2M (+19% q/q), U.S. €6.7M (+29%); FY2026 guidance cut to €33–35M; cash €77.0M; CCC PMA supplement submitted; shares about -13% intraday to about USD 0.96Credibility reset
29 October 2026 (scheduled)Claim construction (Markman) hearing in Inspire v. NyxoahKey litigation milestone
5 November 2026 (scheduled)Full Q3 2026 resultsNext disclosure

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Net revenue rose from EUR 0.8 Mn in FY2021 to EUR 10 Mn in FY2025.
Nyxoah S.A. — Income Statement: Revenue & Gross Profit
Series (EUR Mn)FY2021FY2022FY2023FY2024FY2025
Net revenue0.83.14.34.510
Gross revenue before patch deferral——4.35.111
Cost of goods sold——1.71.5—
Gross profit——2.73—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.